Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05029427
Other study ID # HS24522(B2020:127)
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 28, 2021
Est. completion date December 23, 2022

Study information

Verified date January 2023
Source University of Manitoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blinded, cross-over pilot study comparing the effects of ingesting oats containing high molecular weight β-glucan in reducing blood pressure.


Description:

The pilot study will consist of 2 study periods: one treatment period and one control period. The treatment period will provide food products made from oats containing a total of 4 grams per day high molecular weight (HMW) oat β-glucan, whereas, the control period will provide food products made primarily from wheat with no β-glucan. The study will be located at the Chronic Disease Innovation Centre in Seven Oaks General Hospital, Winnipeg, Canada. The primary objective of this study is to investigate the effect of ingestion of HMW oat β-glucan on ambulatory blood pressure. Participants will be asked to wear an ambulatory blood pressure monitor for 24 hours per day for 3 consecutive days at the beginning and end of each treatment period. This device automatically measures blood pressure every 15-30 minutes during the day and 30 to 60 minutes during the evening. The study has been designed to be conducted virtually. Participants will consent to receive both treatment and control over two 4-week periods online. The participants will be randomized to different orders of treatment, with a 4 week wash out period in between.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date December 23, 2022
Est. primary completion date December 14, 2022
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the trial - Generally healthy male and non-pregnant/lactating female, between the ages of 40-75 - When measured by the ambulatory blood pressure monitor, average systolic blood pressure (between 120 and 150mm Hg) and diastolic blood pressure (between 75 and 100mm Hg) - Willing to comply with protocol requirements - Willing to maintain their current weight and activity level throughout the study - Body mass index 18.5-35kg/m2 Exclusion Criteria: - Female participant who is pregnant, lactating or planning pregnancy during the course of the trial - Body mass index = 18.4 and = 35.1 kg/m2 - If there is a history of a secondary cause of hypertension - Ambulatory blood pressure monitor, systolic blood pressure >150mm Hg or <120mm Hg, diastolic pressure >100mm Hg or <75 mm Hg - Use of medications containing pseudoephedrine or other vasoconstricting agents - Antihypertensive drug treatment, regular high dose nonsteroidal anti-inflammatory drugs (NSAID) treatment and the use of cyclosporine or tacrolimus - Cardiovascular disease including stroke, congestive heart failure, myocardial infarction, unstable angina pectoris, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, temporal ischemic attack within six months prior to screening - Not willing to maintain their regular physical activity level throughout the intervention - Use of omega-3 fatty acid, herbal supplements or weight loss drugs - Diagnosis of diabetes type 1 or type 2 - Scheduled elective surgery or other procedures requiring general anaesthesia during the trial - Any other significant disease or disorder which, in the opinion of the Investigator or study physician, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial - Recent history (within 6 month of screening) or current consumption of >14 drinks per week, (1 drink = 12oz of beer, 5oz of wine or 1.5oz distilled spirits) - Body weight change over 3.5kg for the past 3 months - Smokers and tobacco/snuff/nicotine users - Allergy to oats, wheat, peanut, apple, cherry, blueberry, quinoa, egg white, margarine and vanilla extract. - Regular consumption of supplements which may influence blood pressure/consumption of food supplements targeted to blood pressure lowering within 30 days before and during the study - Participants who have participated in another research trial involving an investigational product in the past 12 weeks

Study Design


Related Conditions & MeSH terms


Intervention

Other:
High molecular weight ß-glucan oat cookies
Two cookies that contains 4g beta glucan made from oats will be consumed per day.
Control wheat based cookies
Two cookies that made from cream of wheat without beta glucan will be consumed per day.

Locations

Country Name City State
Canada Chronic Disease Innovation Centre, Seven Oaks Hospital Winnipeg Manitoba

Sponsors (2)

Lead Sponsor Collaborator
University of Manitoba Agriculture and Agri-Food Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Dietary fibre by 24 hour recall Food recalls will be collected through Automated Self-Administered 24-hour dietary assessment tool and analyzed for consumption of dietary fibre Day 1, 2, and 3 and day 26, 27, and 28 of each study period
Primary Mean systolic blood pressure The mean systolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine Day 1 to 3 and day 26-28 of each study period
Secondary Body weight Body weight will be measured in kg to the nearest 0.1 kg using a digital scale Day 1 and day 28 of each study period
Secondary Waist circumference Waist circumference in cm will be measured in triplicate, to the nearest 0.1 cm at the umbilicus, between the last rib and iliac crest using a fibreglass tape Day 1 and day 28 of each study period
Secondary Mean diastolic blood pressure The mean diastolic blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine Day 1, 2, and 3 and day 26, 27, and 28 of each study period
Secondary Mean arterial blood pressure The mean arterial blood pressure will be measured for 24 hours for 3 consecutive days with an ambulatory blood pressure machine Day 1, 2, and 3 and day 26, 27, and 28 of each study period
See also
  Status Clinical Trial Phase
Completed NCT03626363 - Mindfulness and Neural Cardiovascular Control in Humans N/A
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT04953650 - Intermittent Fasting Towards Elevated Blood Pressure N/A
Enrolling by invitation NCT06033417 - Walking and Blood Pressure in Older Adults With Respiratory Impairment. N/A
Completed NCT03716960 - The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women. N/A
Completed NCT05533268 - Effect of Mental and Physical Training on Blood Pressure N/A
Recruiting NCT05370625 - To Assess TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure N/A
Recruiting NCT04766424 - Sleep Technology Intervention to Target Cardiometabolic Health N/A
Recruiting NCT05297708 - Office, Home, and Ambulatory Blood Pressure
Completed NCT00869193 - Effect of Grape Seed Extract on Blood Pressure N/A
Completed NCT04298944 - Association of Mood With Risk for Atherosclerosis
Recruiting NCT05397535 - Baduanjin Lower Elevated Blood PreSsure Study N/A
Completed NCT05928676 - Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure N/A
Not yet recruiting NCT03764020 - Trial of Oral Melatonin in Elevated Blood Pressure Phase 3
Suspended NCT03508739 - Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition Phase 3
Recruiting NCT05469503 - Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure N/A
Recruiting NCT05955040 - Treatment of Elevated Blood Pressures in Early Pregnancy Phase 2
Completed NCT04003597 - 'Low-salt' Bread as a Means of Reducing Dietary Salt and Lowering Blood Pressure N/A
Recruiting NCT03816462 - ReNEW Clinic Cohort Study